The epidermal growth factor receptor (EGFR) signal transduction pathway plays a prominent role in the development of carcinomas, and is an interesting target for antitumoral therapy. We have previously described how potato carboxypeptidase inhibitor (PCI), a 39-amino acid protease inhibitor with a T-Knot motif, binds to EGFR receptor and inhibits the activation of receptor protein tyrosine kinase. In this paper it is shown that PCI interferes with EGFR activation through inhibition of receptor dimerization and receptor transphosphorylation induced by epidermal growth factor (EGF) and by transforming growth factor alpha (TGF-α). Moreover, PCI blocks the formation and activation of ErbB1/ErbB-2 heterodimers that have a prominent role in carcinoma development. As a result of these effects, PCI interferes in the EGFR signal transduction pathway by reversing the effects of EGF on the growth of two tumoral cell lines, A431 and MDA-MB-453, and promotes EGFR down-regulation. These results show that PCI acts as an EGF/TGF-α antagonist, which suggests its therapeutic potential in the treatment of carcinomas. © 2005 Elsevier Ireland Ltd. All rights reserved.
- EGF antagonist
- Signal transduction
Sitjà-Arnau, M., Molina, M. A., Blanco-Aparicio, C., Ferrer-Soler, L., Lorenzo, J., Avilés, F. X., Querol, E., & De Llorens, R. (2005). Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Letters, 226, 169-184. https://doi.org/10.1016/j.canlet.2005.01.025